{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:47:18Z","timestamp":1791082038496,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We questioned the impact of pregnancy on disease-free survival (DFS) in women with history of breast cancer (BC) according to estrogen receptor (ER) status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A multicenter, retrospective cohort study in which patients who became pregnant any time after BC were matched (1:3) to patients with BC with similar ER, nodal status, adjuvant therapy, age, and year of diagnosis. To adjust for guaranteed time bias, each nonpregnant patient had to have a disease-free interval at least equal to the time elapsing between BC diagnosis and date of conception of the matched pregnant one. The primary objective was DFS in patients with ER-positive BC. DFS in the ER-negative cohort, whole population, and overall survival (OS) were secondary objectives. Subgroup analyses included DFS according to pregnancy outcome and BC\u2013pregnancy interval. With a two-sided \u03b1 = 5% and \u03b2 = 20%, 645 ER-positive patients were required to detect a hazard ratio (HR) = 0.65.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 333 pregnant patients and 874 matched nonpregnant patients were analyzed, of whom 686 patients had an ER-positive disease. No difference in DFS was observed between pregnant and nonpregnant patients in the ER-positive (HR = 0.91; 95% CI, 0.67 to 1.24, P = .55) or the ER-negative (HR = 0.75; 95% CI, 0.51 to 1.08, P = .12) cohorts. However, the pregnant group had better OS (HR = 0.72; 95% CI, 0.54 to 0.97, P = .03), with no interaction according to ER status (P = .11). Pregnancy outcome and BC\u2013pregnancy interval did not seem to impact the risk of relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pregnancy after ER-positive BC does not seem to reduce the risk of BC recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2012.44.2285","type":"journal-article","created":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T01:36:18Z","timestamp":1353375378000},"page":"73-79","source":"Crossref","is-referenced-by-count":194,"title":["Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study"],"prefix":"10.1200","volume":"31","author":[{"suffix":"Jr","given":"Hatem A.","family":"Azim","sequence":"first","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Kroman","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Paesmans","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Gelber","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rotmensz","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"De Mattos-Arruda","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj-Britt","family":"Jensen","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavi","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Piccart","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedro A.","family":"Peccatori","sequence":"additional","affiliation":[{"name":"Hatem A. Azim Jr, Marianne Paesmans, Lieveke Ameye, Evandro de Azambuja, and Martine J. Piccart, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium; Niels Kroman and Maj-Britt Jensen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Shari Gelber, International Breast Cancer Study Group Statistical Centre, Dana-Farber Cancer Institute, Boston, MA; Nicole Rotmensz, Aron Goldhirsch, and Fedro A. Peccatori, European Institute of Oncology, Milan; Barbara..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20134"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9264"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.11.033"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.208"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26649"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-012-0185-5"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.007"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(94)70290-X"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.22.1714"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.006"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39035.667176.55"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1671"},{"key":"B14","first-page":"404","volume":"16","author":"Kranick JA","year":"2010","journal-title":"Breast J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9983-7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.05.018"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8700"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs275"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.04.019"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7689"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24835"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3969"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1643-7"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.44.2285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:15:00Z","timestamp":1653506100000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.44.2285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,1]]}},"alternative-id":["10.1200\/JCO.2012.44.2285"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.44.2285","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}